These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 5344299)

  • 41. [Present-day treatment of parkinsonism in the aged].
    Siegfried J
    Schweiz Rundsch Med Prax; 1973 Oct; 62(40):1202-3. PubMed ID: 4754539
    [No Abstract]   [Full Text] [Related]  

  • 42. [Combination therapy of Parkinson's syndrome using L-dopa and a decarboxylase inhibitor].
    Fischer PA; Schneider E; Jacobi P; Maxion H
    Med Welt; 1973 Nov; 24(45):1742-6. PubMed ID: 4768206
    [No Abstract]   [Full Text] [Related]  

  • 43. [Attempt at treating parkinsonism with L-dopa and Artane].
    Stelmasiak Z; Lackowska H; Maksymowicz B
    Pol Tyg Lek; 1971 Aug; 26(34):1325-6. PubMed ID: 5110789
    [No Abstract]   [Full Text] [Related]  

  • 44. [Accomplishment of the treatment and evaluation of treatment alternatives in parkinsonism].
    Presthus J
    Tidsskr Nor Laegeforen; 1973 Oct; 93(28):2119. PubMed ID: 4773985
    [No Abstract]   [Full Text] [Related]  

  • 45. [Changes of blood pressure, pulse and electrolytes following long-term treatment of Parkinsonism using Ro 8-0576 (L-Dopa and decarboxylase inhibitor)].
    Eisenlohr JJ; Gehlen W
    Nervenarzt; 1975 Mar; 46(3):128-35. PubMed ID: 805381
    [No Abstract]   [Full Text] [Related]  

  • 46. [Effect of a decarboxylase inhibitor (Ro 4-4602) and L-dopa on inhibited depressions. II. Experimental psychological studies].
    Pohlmeier H; Schön I; Matussek N
    Arzneimittelforschung; 1970 Jul; 20(7):932-3. PubMed ID: 4918920
    [No Abstract]   [Full Text] [Related]  

  • 47. Coupling of hypotensive and anit-Parkinson effects with two dopaminergic drugs.
    Düby SE; Dahl LK; Cotzias GC
    Trans Assoc Am Physicians; 1971; 84():289-96. PubMed ID: 5164305
    [No Abstract]   [Full Text] [Related]  

  • 48. [A new determination method of L-dopa in blood (author's transl)].
    Weitbrecht WU; Birg W; Metzel E; Mundinger F
    Med Klin; 1974 Mar; 69(12):500-1. PubMed ID: 4831452
    [No Abstract]   [Full Text] [Related]  

  • 49. [Treatment of parkinsonism with L-Dopa associated with decarboxylase inhibitors. II].
    Gauthier G; de Ajuriaguerra J; Simona B; Constantinidis J; Eisenring JJ; Krassoievitch M; Yanniotis G; Tissot R
    Rev Neurol (Paris); 1970 Nov; 123(5):297-319. PubMed ID: 5513630
    [No Abstract]   [Full Text] [Related]  

  • 50. Therapeutic guidelines and side effects encountered during L-dopa therapy in 100 cases of parkinsonism.
    Jenkins AC; Schwieger AC
    Med J Aust; 1971 Oct; 2(14):693-700. PubMed ID: 5114186
    [No Abstract]   [Full Text] [Related]  

  • 51. L-dopa and amantadine for Parkinsonism.
    Drug Ther Bull; 1970 Aug; 8(17):65-7. PubMed ID: 5480244
    [No Abstract]   [Full Text] [Related]  

  • 52. Modification of levodopa effect by systemic decarboxylase inhibition.
    Mars H
    Arch Neurol; 1973 Feb; 28(2):91-5. PubMed ID: 4683155
    [No Abstract]   [Full Text] [Related]  

  • 53. [Action of amantadine HCl alone and in combination with L-dopa on parkinsonism].
    Danielczyk W; Korten JJ
    Med Monatsschr; 1971 Oct; 25(10):472-9. PubMed ID: 5122447
    [No Abstract]   [Full Text] [Related]  

  • 54. [Effect of a decarboxylase inhibitor (Ro 4-4602) in combination with L-dopa on inhibited depressions].
    Matussek N; Benkert O; Schneider K; Otten H; Pohlmeier H
    Arzneimittelforschung; 1970 Jul; 20(7):934-5. PubMed ID: 4918921
    [No Abstract]   [Full Text] [Related]  

  • 55. "Long term evaluation of combined treatment of Parkinson disease with L-dopa, peripheral decarboxylase inhibitors and bromocreptine".
    Caraceni T; Giovannini P; Girotti F; Parati E; Pederzoli M; Scigliano G
    Ital J Neurol Sci; 1981 Dec; 2(4):337-42. PubMed ID: 7333824
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A clinico-biochemical correlation in a Parkinsonian patient treated with levodopa and decarboxylase inhibitor (Ro 4-4602). A model study.
    Sroka H; Eichhorn F; Rutenberg A; Radwan H; Bornstein B
    J Neurol Sci; 1972 Sep; 17(1):61-8. PubMed ID: 5057196
    [No Abstract]   [Full Text] [Related]  

  • 57. Parkinson's disease: L-dopa treatment and handwriting area.
    Knopp W; Paulson G; Allen JN; Smeltzer D; Brown FD; Kose W
    Curr Ther Res Clin Exp; 1970 Mar; 12(3):115-25. PubMed ID: 4985489
    [No Abstract]   [Full Text] [Related]  

  • 58. [Dopa metabolism in relation to the therapy of Parkinson's syndrome].
    Pletscher A; Bartholini G
    Actual Pharmacol (Paris); 1971; 24():27-49. PubMed ID: 5150621
    [No Abstract]   [Full Text] [Related]  

  • 59. Brocresine in Parkinson's disease. Action of a peripheral and central decarboxylase inhibitor in potentiating levodopa.
    Howse PM; Matthews WB
    J Neurol Neurosurg Psychiatry; 1973 Feb; 36(1):27-9. PubMed ID: 4570903
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Effects of simultaneous administration of pyridoxine in the combined administration of L-dopa and peripheral decarboxylase inhibitors. Experimental and clinical studies].
    Namba S; Omoto T; Kishikawa H
    No To Shinkei; 1976 Aug; 28(8):815-22. PubMed ID: 829033
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.